As gov­ern­ment fund­ing dries up, Pfiz­er ex­pects to charge pri­vate pay­ers $110+ for Covid-19 vac­cine

For months, com­pa­nies be­hind Covid-19 vac­cines and ther­a­pies have been talk­ing about tran­si­tion­ing to a pri­vate com­mer­cial mar­ket once the gov­ern­ment fund­ing dries up. As its pur­chase pro­gram with the US comes to an end, Pfiz­er is putting a dol­lar fig­ure to the dis­cus­sion.

Pfiz­er plans to charge $110 to $130 for its BioN­Tech-part­nered Covid-19 shot, al­most qua­dru­pling the price, An­gela Lukin, glob­al pri­ma­ry care & US pres­i­dent, told Reuters and Wall Street Jour­nal.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER